# Quantitative Susceptibility Mapping in Skull Base Chordoma: In Silico Analysis and In Vivo Application Towards Indirect Hypoxia Assessment

**Authors:** P. Fenech, L. Morelli, G. Parrella, S. Imparato, A. Iannalfi, S. Lillo, E. Orlandi, G. Baroni, C. Paganelli

PMC · DOI: 10.1002/mrm.70193 · 2025-11-24

## TL;DR

This study explores using QSM to assess hypoxia in skull base chordomas through simulations and patient data, showing promising results for non-invasive tumor characterization.

## Contribution

The study introduces an optimized QSM pipeline for skull base chordomas and demonstrates its potential for indirect hypoxia assessment.

## Key findings

- The optimized QSM pipeline achieved a phase unwrapping error of 38.36 ppm and background field removal error between 49 and 53 Hz.
- QSM features correlated significantly with Ki-67 in SBC patients, with Spearman's coefficients of 0.8 and -0.8.
- A binary classifier based on QSM features achieved 85.7% accuracy in distinguishing low- and high-proliferation tumors.

## Abstract

To evaluate quantitative susceptibility mapping (QSM) beyond the brain through realistic simulations and to explore preliminary evidence that may be indicative of hypoxia in skull base chordomas (SBC).

Each step of the QSM pipeline was optimized within an in silico framework consisting of (i) phase unwrapping, (ii) background field removal, and (iii) dipole field inversion, which were tested on a realistic phantom to generate accurate susceptibility maps. The optimized pipeline was then applied to seven SBC patients, analyzing tumor heterogeneity and correlating QSM features with the proliferation index (Ki‐67), towards hypoxia assessment. A binary classifier was developed to distinguish low‐ and high‐proliferation tumors based on first‐order QSM features.

The optimal phase unwrapping method combined with dipole inversion provided an error of 38.36 ppm. The best strategy for background field removal exhibited the lowest error (from 49 to 53 Hz). In SBC patients, tumor heterogeneity was observed, and a statistically significant correlation (p < 0.05) was measured between Ki‐67 versus QSM maximum value and interquartile coefficient of variation within the tumor volume (Spearman's coefficients of 0.8 and −0.8, respectively). The classifier achieved 85.7% accuracy.

This study provides a foundation for characterizing SBC through QSM, enabling indirect, non‐invasive identification of potentially hypoxic tumor regions. Further histological validation with specific hypoxia markers, such as HIF‐1α, is nevertheless required.

## Linked entities

- **Proteins:** Mki67 (antigen identified by monoclonal antibody Ki 67), HIF1A (hypoxia inducible factor 1 subunit alpha)

## Full-text entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}
- **Diseases:** tumor (MESH:D009369), hypoxic (MESH:D002534), Base Chordoma (MESH:D002817), Hypoxia (MESH:D000860), SBC (MESH:D019292)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12850577/full.md

---
Source: https://tomesphere.com/paper/PMC12850577